What is Charles River Laboratories?
Charles River Laboratories is a drug discovery and development services company serving enterprise, public-sector, commercial, consumer, or regulated-market customers.
- Category
- Drug discovery and development services
- Headquarters
- Wilmington, MA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; NYSE: CRL
What is Charles River Laboratories?
Charles River Laboratories is a drug discovery and development services company headquartered in Wilmington, MA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Charles River Laboratories is a drug discovery and development services company headquartered in Wilmington, MA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Charles River Laboratories should be mapped as a scaled public-company account rather than an early-stage company. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Charles River Laboratories offer?
Charles River Laboratories's profile centers on Research models, Discovery services, Safety assessment, Manufacturing support.
- Research models· Drug discovery and development services
- Discovery services· Drug discovery and development services
- Safety assessment· Drug discovery and development services
- Manufacturing support· Drug discovery and development services
- Biologics testing· Drug discovery and development services
- Lab services· Drug discovery and development services
How does Charles River Laboratories make money?
Charles River Laboratories makes money through commercial activity tied to drug discovery and development services.
Charles River Laboratories monetizes through the model common to drug discovery and development services: product sales, recurring services, subscriptions, contracts, distribution, transaction volume, underwriting, regulated utility revenue, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, uptime, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Charles River Laboratories?
Charles River Laboratories's named executives should be verified on the official leadership or investor-relations page before outreach.
- Charles River Laboratories executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Charles River Laboratories finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Charles River Laboratories operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Charles River Laboratories's leadership?
Charles River Laboratories should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.criver.com- Charles River Laboratories investor relationsInvestor relations / corporate contactcontact via https://www.criver.com
- Charles River Laboratories sales or partnershipsCommercial contact routecontact via https://www.criver.com
- Charles River Laboratories media relationsMedia or communications contact routecontact via https://www.criver.com
How is Charles River Laboratories funded?
Charles River Laboratories's current status is Public company; NYSE: CRL.
Charles River Laboratories's capital profile is best understood through its current public-company status: Public company; NYSE: CRL. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capex plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Charles River Laboratories get here?
Charles River Laboratories's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingCharles River Laboratories is foundedThe company begins building in drug discovery and development services.
- Scale-upCommercial footprint expandsCharles River Laboratories broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; NYSE: CRLPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Charles River Laboratories's competitors?
Charles River Laboratories competes with larger incumbents and focused specialists in drug discovery and development services.
- Thermo Fisher ScientificLife sciences tools, diagnostics, and services incumbent.
- DanaherLife sciences and diagnostics platform company.
- MedtronicGlobal medical technology competitor.
- PfizerLarge pharmaceutical company with global commercial reach.
- IQVIAHealthcare data and clinical research platform competitor.
Charles River Laboratories — frequently asked questions
